SHORT DURATION OF CONVENTIONAL SYNTHETIC DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS (CSDMARDS) BEFORE AND AFTER BECOMING A CSDMARD INADEQUATE RESPONDER (IR) IN RHEUMATOID ARTHRITIS (RA) PATIENTS

被引：0
|
作者：
Dore, R. K.
Antonova, J. [1 ]
Huang, H. [2 ]
Gorritz, M. [3 ]
Genovese, M. C. [4 ]
机构：
[1] Gilead Sci, Foster City, CA USA
[2] IQVIA, Cambridge, MA USA
[3] IQVIA, Plymouth Meeting, PA USA
[4] Stanford Univ, Stanford, CA 94305 USA
来源：
VALUE IN HEALTH | 2019年 / 22卷
关键词：
D O I：
10.1016/j.jval.2019.04.749
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PDG70
引用
收藏
页码：S174 / S174
页数：1
相关论文
共 50 条
  • [1] SHORT DURATION OF CONVENTIONAL SYNTHETIC DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS (CSDMARDS) BEFORE AND AFTER BECOMING A CSDMARD INADEQUATE RESPONDER IN RHEUMATOID ARTHRITIS PATIENTS
    Dore, Robin K.
    Antonova, Jenya
    Huan, Huang
    Gorritz, Magdaliz
    Genovese, Mark C.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2019, 78 : 700 - 700
  • [2] EFFICACY AND SAFETY OF UPADACITINIB IN A CHINESE SUBGROUP OF PATIENTS WITH RHEUMATOID ARTHRITIS AND INADEQUATE RESPONSE TO CONVENTIONAL SYNTHETIC DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS
    Zeng, X.
    Liu, Y.
    Hu, J.
    Li, J.
    Wang, Y.
    Zhao, D.
    Wu, L.
    Xiao, Z.
    Li, Z.
    Xu, J.
    Meerwein, S.
    Xie, Y.
    Liang, P.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2022, 81 : 1324 - 1324
  • [3] Optimizing outcomes in rheumatoid arthritis patients with inadequate responses to disease-modifying anti-rheumatic drugs
    Pavelka, Karel
    Kavanaugh, Arthur F.
    Rubbert-Roth, Andrea
    Ferraccioli, Gianfranco
    [J]. RHEUMATOLOGY, 2012, 51 : V12 - V21
  • [4] Effect of Upadacitinib on Pain and Morning Stiffness in Patients with Rheumatoid Arthritis and Inadequate Response to Conventional Synthetic or Biologic Disease-Modifying Anti-Rheumatic Drugs
    Wells, Alvin E.
    Lee, Yvonne C.
    Tundia, Namita
    Suboticki, Jessica
    Chen, Kun
    Friedman, Alan
    Strand, Vibeke
    [J]. ARTHRITIS & RHEUMATOLOGY, 2018, 70
  • [5] RHEUMATOID-ARTHRITIS - DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS
    KIRWAN, JR
    CURREY, HLF
    [J]. CLINICS IN RHEUMATIC DISEASES, 1983, 9 (03): : 581 - 599
  • [6] The use of conventional disease-modifying anti-rheumatic drugs in established RA
    Jurgens, M. S.
    Jacobs, J. W. G.
    Bijlsma, J. W. J.
    [J]. BEST PRACTICE & RESEARCH IN CLINICAL RHEUMATOLOGY, 2011, 25 (04): : 523 - 533
  • [7] Can we discontinue synthetic disease-modifying anti-rheumatic drugs in rheumatoid arthritis?
    Scott, I. C.
    Kingsley, G. H.
    Scott, D. L.
    [J]. CLINICAL AND EXPERIMENTAL RHEUMATOLOGY, 2013, 31 (04) : S4 - S8
  • [8] Retention rates of disease-modifying anti-rheumatic drugs in patients with rheumatoid arthritis
    Agarwal, S.
    Zaman, T.
    Handa, R.
    [J]. SINGAPORE MEDICAL JOURNAL, 2009, 50 (07) : 686 - 692
  • [9] THE EFFECT OF BIOLOGICAL AND CONVENTIONAL DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS ON FATIGUE IN FIBROMYALGIC RHEUMATOID ARTHRITIS PATIENTS
    Hizmetli, S.
    Durmaz, Y.
    Kaptanoglu, E.
    Cengiz, A. K.
    Peksen, H.
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2013, 72 : 864 - 864
  • [10] Predictors of disease flare following tapering of conventional synthetic disease-modifying anti-rheumatic drugs in rheumatoid arthritis remission
    Sundlisaeter, N. P.
    Sexton, J.
    Aga, A.
    Uhlig, T.
    Solomon, D. H.
    Van der Heijde, D.
    Kvien, T. K.
    Haavardsholm, E. A.
    Lillegraven, S.
    [J]. SCANDINAVIAN JOURNAL OF RHEUMATOLOGY, 2021, 50 : 10 - 11
12345